Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including …
Post
-
-
How one US state is tackling the drug affordability crisis
Drug affordability remains a key priority for the US government as it negotiates with pharma companies to lower individual drug …
-
Johnson & Johnson acquires Halda Therapeutics for $3.05bn
Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash. This move …
-
Enriched patient data needed to uncover sex differences in Alzheimer’s trials
Researchers say that women are twice as likely to develop Alzheimer’s disease as men. However, despite recent advances in treatments …
-
Sanofi buys hep B vaccine maker for $2.2bn
Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former's …
-
Revamping best-selling drugs to combat patent cliff has limits
As the looming patent cliff approaches, some major blockbuster drugs are set to lose their exclusivity, with pharma companies making …
-
Innovent receives NMPA approval for Tabosun colon cancer treatment
Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application (NDA) for Tabosun (ipilimumab …
-
Gilead Sciences to acquire Repare’s RP-3467
Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467. The transaction involves a total …
-
Zydus and Bioeq partner for commercialisation of Nufymco in US
Zydus Lifesciences Global FZE, a subsidiary of Zydus, has entered into an agreement with Bioeq for the US commercialisation of …
-
Alternative commercialisation models offer lifeline to future of gene therapies
Cell and gene therapies (CGTs) have captured significant interest in the pharma industry, with the modality being explored in multiple …
-
Ipsen outlays $1bn for China-based Simcere’s preclinical ADC
Ipsen has added a Chinese-developed antibody drug conjugate (ADC) to its pipeline in a deal that could top $1bn, cementing …
-
Magazine: Biopharma’s 2025 M&A boom
As we head into the new year, now is the time to look back on the activity seen in the …
-
Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma
Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration’s (FDA) accelerated approval for Lunsumio …
-
Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity
Novo Nordisk has ushered in a new era of obesity treatment – gaining the first US Food and Drug Administration …
-
Samsung Biologics to acquire Human Genome Sciences
Samsung Biologics has entered into a definitive agreement, through its subsidiary Samsung Biologics America, to acquire Human Genome Sciences from …
